Azithromycin plus chloroquine + sulfadoxine-pyrimethamine
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intermittent Preventive Treatment In Pregnancy (IPTp)
Conditions
Intermittent Preventive Treatment In Pregnancy (IPTp)
Trial Timeline
Oct 1, 2010 → Nov 1, 2013
NCT ID
NCT01103063About Azithromycin plus chloroquine + sulfadoxine-pyrimethamine
Azithromycin plus chloroquine + sulfadoxine-pyrimethamine is a phase 3 stage product being developed by Pfizer for Intermittent Preventive Treatment In Pregnancy (IPTp). The current trial status is terminated. This product is registered under clinical trial identifier NCT01103063. Target conditions include Intermittent Preventive Treatment In Pregnancy (IPTp).
What happened to similar drugs?
1 of 1 similar drugs in Intermittent Preventive Treatment In Pregnancy (IPTp) were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01103063 | Phase 3 | Terminated |
Competing Products
12 competing products in Intermittent Preventive Treatment In Pregnancy (IPTp)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg | AstraZeneca | Approved | 43 |
| LLG783 + Placebo | Novartis | Phase 2 | 35 |
| ataciguat (HMR1766) + placebo + cilostazol | Sanofi | Phase 2 | 35 |
| Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 | Sanofi | Phase 2 | 35 |
| SL650472, Clopidogrel | Sanofi | Phase 2 | 35 |
| Givosiran | Alnylam Pharmaceuticals | Phase 1/2 | 29 |
| Givosiran + 5-probe cocktail | Alnylam Pharmaceuticals | Phase 1 | 26 |
| givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| Sapropterin Dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 32 |
| Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine | BioMarin Pharmaceutical | Phase 1 | 33 |
| Placebo + 375 mg CK-2017357 + 500 mg CK-2017357 | Cytokinetics | Phase 2 | 32 |
| Pimavanserin 34 mg + Placebo | Acadia Pharmaceuticals | Phase 2 | 39 |